Horizon Therapeutics plc
https://www.horizontherapeutics.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Horizon Therapeutics plc
2023-2024 Global Biopharma R&D Productivity And Growth Ranking
The overall R&D productivity of the 30 largest public biopharma companies has increased despite a challenging global environment for investment and growth. Will hype cycles impact this picture in coming years?
Amgen Phase III Data Could Add Second Indication To Uplizna’s Label
Amgen’s study shows an 87% risk-reduction for IgG4-related disease flares, which can exacerbate the rare disorder and lead to irreversible organ failure. A US filing is planned.
Stock Watch: Paradoxical Q1 Earnings Reactions
Falling sales are not typically welcomed by investors, while good revenue growth is prized. The first-quarter earnings season provided exceptions to this rule, and then there was Amgen.
FTC Is Taking A Tougher Stance On Pharma, A Deputy Director Explains Why
Rahul Rao, the deputy director of the FTC Bureau of Competition, discussed the agency’s thinking on recent pharma deals that it viewed as anti-competitive.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Bio-Technology General Corporation
- Crealta Holdings LLC
- Crealta Pharmaceuticals
- Curzion Pharmaceuticals, Inc.
- Encode Pharmaceuticals, Inc.
- Horizon Pharma plc
- Hyperion Therapeutics, Inc. (Andromeda Biotech Ltd)
- Nitec Pharma AG
- Raptor Pharmaceutical Corp.
- River Vision Development Corp.
- Savient Pharmaceuticals, Inc. (SVNT)
- TorreyPines Therapeutics, Inc. (Neurogenetics Inc.)
- Vidara Therapeutics Inc
- Viela Bio, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice